Go Back
Go Back

Day 2

22 Ch. Veros - FGFR mut

22 Ch. Veros - FGFR mut

23 Ch. Panopoulos - MSI-H & IDH1 mutant

23 Ch. Panopoulos - MSI-H & IDH1 mutant

24 D. Matthaios - wt Cholangiocarcinoma

24 D. Matthaios - wt Cholangiocarcinoma

25 J. Marquardt - Research perspectives of CCA

25 J. Marquardt - Research perspectives of CCA

26 V. Lampadiari - Diabetes & PDAC. Myth vs Reality

26 V. Lampadiari - Diabetes & PDAC. Myth vs Reality

27 G. Papaxoinis - Short Debate: What is clinically relevant: Molecular subtyping versus Genetic Predisposition?

27 G. Papaxoinis - Short Debate: What is clinically relevant...

28 P.Apostolou - What is clinically relevant: Molecular subtyping versus Genetic Predisposition?

28 P.Apostolou - What is clinically relevant: Molecular subt...

29 Ch. Salla - Cytopathology of Pancreatic Lesions for non-cytopathologists

29 Ch. Salla - Cytopathology of Pancreatic Lesions for non-c...

30 V. Sivanathan - IPMN diagnosis, screening and treatment

30 V. Sivanathan - IPMN diagnosis, screening and treatment

31 G. Tsiotos - Surgical management

31 G. Tsiotos - Surgical management

32 G. Nintos - Neoadjuvant chemo/irradiation; alternatives to FOLFIRINOX.

32 G. Nintos - Neoadjuvant chemo/irradiation; alternatives t...

33 B. Brenner - Systemic treatment for inoperable disease: Which is the optimal 1st line

33 B. Brenner - Systemic treatment for inoperable disease: W...

34 S. Pappas - Robotic Pancreatectomy

34 S. Pappas - Robotic Pancreatectomy

35 G. Oestreicher - Improvingquality of life of advanced pancreatic cancer patients through an AI- guided multi- modal intervention.

35 G. Oestreicher - Improvingquality of life of advanced pan...

36 A. Chremou - Postoperative nutritional support after pancreatectomy

36 A. Chremou - Postoperative nutritional support after panc...